iShares U.S. Pharmaceuticals ETF (IHE)
| Assets | $1.68B |
| Expense Ratio | 0.37% |
| PE Ratio | 22.40 |
| Shares Out | 16.30M |
| Dividend (ttm) | $1.43 |
| Dividend Yield | 1.42% |
| Ex-Dividend Date | Sep 15, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 31.20% |
| Volume | 198,096 |
| Open | 103.60 |
| Previous Close | 102.92 |
| Day's Range | 100.88 - 103.60 |
| 52-Week Low | 69.02 |
| 52-Week High | 108.66 |
| Beta | 0.50 |
| Holdings | 57 |
| Inception Date | May 1, 2006 |
About IHE
Fund Home PageThe iShares U.S. Pharmaceuticals ETF (IHE) is an exchange-traded fund that is based on the DJ US Select / Pharmaceutical index. The fund tracks a broad-based, cap-weighted index of US pharmaceutical companies. IHE was launched on May 1, 2006 and is issued by BlackRock.
Top 10 Holdings
77.97% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 23.20% |
| Johnson & Johnson | JNJ | 22.47% |
| Merck & Co., Inc. | MRK | 4.56% |
| Pfizer Inc. | PFE | 4.48% |
| Zoetis Inc. | ZTS | 4.43% |
| Bristol-Myers Squibb Company | BMY | 4.31% |
| Viatris Inc. | VTRS | 4.31% |
| Royalty Pharma plc | RPRX | 4.31% |
| Jazz Pharmaceuticals plc | JAZZ | 3.41% |
| Elanco Animal Health Incorporated | ELAN | 2.50% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 15, 2026 | $0.27888 | Sep 18, 2026 |
| Jun 15, 2026 | $0.28478 | Jun 18, 2026 |
| Mar 17, 2026 | $0.28449 | Mar 20, 2026 |
| Dec 16, 2025 | $0.58525 | Dec 19, 2025 |
| Sep 16, 2025 | $0.3124 | Sep 19, 2025 |
| Jun 16, 2025 | $0.30654 | Jun 20, 2025 |
Performance
IHE had a total return of 46.47% in the past year, including dividends. Since the fund's inception, the average annual return has been 10.86%.
News
Nikkei 225, Kospi jolt Asian markets as AI rout and Fed fears collide
Asian stocks were mixed on Thursday as investors assessed the fallout from the AI sell-off, the Federal Reserve's rate outlook and renewed tensions in the Middle East. The MSCI Asia-Pacific gauge excl...
Kospi jumps 6% as Asia's battered semiconductor trade rebounds
Asian stocks rallied on Wednesday as investors returned to semiconductor shares after a bruising sell-off, taking their cue from a Wall Street rebound even as Brent crude pushed further above $91 a ba...
US FDA to review AI-based tool to predict drug-related liver damage
The U.S. FDA's Center for Drug Evaluation and Research said on Wednesday it has accepted a letter of intent for an artificial intelligence-based drug development tool designed to help predict drug-i...
Trump to announce discount drug pricing expansion, White House official says
U.S. President Donald Trump will announce a dramatic expansion of TrumpRx.gov, a government-backed website offering discounted prescription drugs under his administration's pricing deal, on Monday, ...
US FDA to monitor clinical trial data in real time in pilot program aimed at speeding approvals
The U.S. Food and Drug Administration launched a pilot program on Monday aimed at allowing the agency to monitor clinical trial data in real time, a step the agency said could cut years from drug ap...
Could pressure to make money faster kill the next lifesaving pill?
When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.
Britain agrees full text of US-UK pharmaceutical trade deal
Britain said on Thursday it had agreed the full text of a U.S.-UK pharmaceutical partnership, setting out terms under which British-made medicines would enter the United States tariff-free.
Big Pharma Unfazed by Trump Tariffs, But Small Biotechs Face Vulnerability
Drugmakers have been bracing for levies and sought to get ahead of them with pledges to invest billions more on domestic manufacturing.
Trump announces 100% tariffs on pharmaceutical drugs, beginning October 1
President Donald Trump said Thursday that he will put import taxes of 100% on pharmaceutical drugs, 50% on kitchen cabinets and bathroom vanities, 30% on upholstered furniture and 25% on heavy trucks ...
Pharma stocks gain, as Trump's tariff move actually could be a win for the sector
Pharmaceutical stocks mostly gained Friday, as traders appeared to shrug off or even cheer President Donald Trump's rollout of a new tariff plan for drugmakers.
Trump teases targeted tariffs on overseas drug manufacturers
With the next set of White House–imposed tariffs just hours away from taking effect — including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. — ...
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-...
Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April
Hello! This week's ETF Wrap digs into the slump in ETF flows in April and investor positioning around commodities as inflation worries persist.
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade
A new ETF hit the market Tuesday, creating buzz for its exposure to popular weight-loss drugs, while expanding the roster of thematic ETFs available for investors willing to pay up for stock-picking p...
Best Pharmaceutical ETFs for Q1 2021
The best pharmaceutical ETFs for Q1 2021 are KURE, XPH, and IHE.